Fundamental Analysis of NUVALENT INC-A(NASDAQ:NUVL) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NUVL. NUVL was compared to 572 industry peers in the Biotechnology industry. NUVL has a great financial health rating, but its profitability evaluates not so good. NUVL is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NUVL has reported negative net income.

NUVL had a negative operating cash flow in the past year.

In the past 5 years NUVL always reported negative net income.

In the past 5 years NUVL always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -18.87%, NUVL is in the better half of the industry, outperforming 79.29% of the companies in the same industry.

NUVL has a better Return On Equity (-20.01%) than 84.96% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.87%
ROE	-20.01%
ROIC	N/A

ROA(3y)-16.66%

ROA(5y)-109.04%

ROE(3y)-17.32%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NUVL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for NUVL has been increased compared to 1 year ago.

NUVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 45.48 indicates that NUVL is not in any danger for bankruptcy at the moment.

NUVL's Altman-Z score of 45.48 is amongst the best of the industry. NUVL outperforms 98.58% of its industry peers.

NUVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	45.48

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 23.07 indicates that NUVL has no problem at all paying its short term obligations.

NUVL's Current ratio of 23.07 is amongst the best of the industry. NUVL outperforms 96.11% of its industry peers.

NUVL has a Quick Ratio of 23.07. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.

NUVL has a better Quick ratio (23.07) than 96.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	23.07
Quick Ratio	23.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for NUVL have decreased strongly by -70.94% in the last year.

EPS 1Y (TTM)-70.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-116.95%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.59% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-84.82%

EPS Next 2Y-47.43%

EPS Next 3Y-32.38%

EPS Next 5Y13.59%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NUVL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NUVL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NUVL's earnings are expected to decrease with -32.38% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-47.43%

EPS Next 3Y-32.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NUVL!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NUVALENT INC-A

NASDAQ:NUVL (1/15/2025, 9:41:15 AM)

75.04

+2.65 (+3.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners99.38%

Inst Owner Change0%

Ins Owners3.14%

Ins Owner Change2.65%

Market Cap5.33B

Analysts86

Price Target117.81 (57%)

Short Float %9.38%

Short Ratio12.34

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-23.51%

Min EPS beat(2)-33.94%

Max EPS beat(2)-13.07%

EPS beat(4)1

Avg EPS beat(4)-11.9%

Min EPS beat(4)-33.94%

Max EPS beat(4)0.55%

EPS beat(8)4

Avg EPS beat(8)-4.74%

EPS beat(12)7

Avg EPS beat(12)-1.48%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)2.76%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-33.79%

EPS NY rev (1m)0.8%

EPS NY rev (3m)-12.44%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	4.76
P/tB	4.76
EV/EBITDA	N/A

EPS(TTM)-3.47

EYN/A

EPS(NY)-4.7

Fwd EYN/A

FCF(TTM)-2.16

FCFYN/A

OCF(TTM)-2.16

OCFYN/A

SpS0

BVpS15.78

TBVpS15.78

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.87%
ROE	-20.01%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-16.66%

ROA(5y)-109.04%

ROE(3y)-17.32%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	23.07
Quick Ratio	23.07
Altman-Z	45.48

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-70.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-116.95%

EPS Next Y-84.82%

EPS Next 2Y-47.43%

EPS Next 3Y-32.38%

EPS Next 5Y13.59%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-81.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-79.74%

EBIT Next 3Y-35.96%

EBIT Next 5YN/A

FCF growth 1Y-154.86%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-154.86%

OCF growth 3YN/A

OCF growth 5YN/A

NUVALENT INC-A (NUVL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens